Amyloid imaging: Liberal or conservative? Let the data decide

Archives of Neurology

Volumn 68, Issue 11, 2011, Pages 1377-1378

  Jagust, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; AUTOPSY; BRAIN BIOPSY; CEREBELLUM; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NORMOTENSIVE HYDROCEPHALUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE RATIO;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; BENZOTHIAZOLES; CEREBRAL CORTEX; DEMENTIA; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 81355154202     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.152     Document Type: Editorial

References (12)

1. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
4. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease [published online July 11, 2011]. Arch Neurol. 2011; 68(11):1404-1411.
5. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology [published online July 11, 2011]. Arch Neurol. 2011;68(11):1398-1403.
6. Clark CM, Schneider JA, Bedell BJ, et al.; AV45-A07 Study Group. Use of florbetapir- PET for imaging beta-amyloid pathology [published correction appears in JAMA. 2011;305(11):1096]. JAMA. 2011;305(3):275-283.
7. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73(10):754-760.
8. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes [published correction appears in Ann Neurol. 2009;66(1):123]. Ann Neurol. 2009;65(5):557-568.
9. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181-192.
10. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-329.
11. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304-1309.
12. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630-1645. (Pubitemid 351806448)